Sign up for this panel discussion by clicking the green "Click to Register" button in the upper right corner. Then confirm your registration via email.

Industry and clinical experts will discuss the future of gene therapies in addressing vision diseases, including the major milestones achieved to date and the significant advances on the horizon. 

Alexander Anetakis, MD, MBA, Vitreo-retinal Surgeon, UPMC, and Physician-Advisor, UPMC Enterprises (Moderator)

Dan Chung, MD, Chief Medical Officer, SparingVision

Rob Lin, PhD, CFA, Chief Executive Officer, Avista Therapeutics

Long-term efficacy of gene therapies and degeneration over time.

Challenges with manufacturing gene therapies.

Addressing the high costs and accessibility of gene therapies.

Optimizing delivery methods for gene therapies.

Potential for combinations of gene therapy and other treatments, such as drugs or stem cell therapies.

What is needed to expand targets for gene therapies beyond specific mutations.

A Vision of the Future: Advancing Gene Therapies to Treat Eye Diseases